Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options: results from a phase I study
Lenalidomide is an immunomodulatory drug approved for multiple myeloma, relapsed mantle cell lymphoma and myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)). Based on the high rate of hematologic improvement and cytogenetic responses seen in del(5q) MDS, several trials have been
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
February 2019
|
| In: |
Haematologica
Year: 2019, Jahrgang: 104, Heft: 2, Pages: e63-e64 |
| ISSN: | 1592-8721 |
| DOI: | 10.3324/haematol.2018.199794 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.3324/haematol.2018.199794 Verlag, Volltext: http://www.haematologica.org/content/104/2/e63 
|
| Verfasserangaben: | Marie Luise Hütter-Krönke, Walter Fiedler, Andrea Kündgen, Jürgen Krauter, Marie von Lilienfeld-Toal, Hartmut Döhner, Richard F. Schlenk |
| Zusammenfassung: | Lenalidomide is an immunomodulatory drug approved for multiple myeloma, relapsed mantle cell lymphoma and myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)). Based on the high rate of hematologic improvement and cytogenetic responses seen in del(5q) MDS, several trials have been |
|---|---|
| Beschreibung: | Gesehen am 28.02.2019 |
| Beschreibung: | Online Resource |
| ISSN: | 1592-8721 |
| DOI: | 10.3324/haematol.2018.199794 |